Sartorius Stedim Biotech and Repligen Corporation Partner to
Introduce Next-Generation Perfusion-Enabled Bioreactors
Sartorius Stedim Biotech (SSB) (Euronext: DIM), a leading
international supplier for the biopharmaceutical industry, and
Repligen Corporation (NASDAQ:RGEN), a global life sciences company
focused on bioprocessing technologies, have entered into a
collaboration agreement to integrate Repligen’s XCell™ ATF cell
retention control technology into SSB’s BIOSTAT® STR large-scale
single-use bioreactors to create novel perfusion-enabled
bioreactors. As a result of this collaboration, end users will
stand to benefit from a single control system for 50 L to 2,000 L
bioreactors used in perfusion cell culture applications. This
single interface is designed to control cell growth, fluid
management and cell retention in continuous and intensified
bioprocessing and, ultimately, simplify the development and cGMP
manufacture of biological drugs.
Through the partnership, Sartorius Stedim
Biotech and Repligen will further collaborate to equip SSB’s
recently launched ambr® 250ht perfusion single-use mini bioreactor
system with Repligen’s KrosFlo® hollow fiber filter technology. The
bioreactor system will be sold by SSB as a complete single-use
assembly. This optimal design conserves hollow fiber filter
technology across scales, enabling customers to fast track
development and scale up their cell culture perfusion
processes.
“Sartorius Stedim Biotech has continuously
expanded its integrated upstream portfolio over the past years with
a focus on robust and scalable, automated single-use solutions,
optimized for high-cell-density applications. The collaboration
with Repligen will result in easy-to-implement, high-performance
and perfusion-ready bioreactors ranging from process development to
commercial manufacturing scale,” commented Stefan Schlack, Head of
Marketing at SSB.
Christine Gebski, Vice President of Product
Management at Repligen, stated, “We are excited to partner with
Sartorius Stedim Biotech, a global innovator in bioreactor
technology. The integration of our market-leading XCell™ ATF
control technology with SSB’s high-performance bioreactors offers a
simplified perfusion-enabled bioreactor solution for end users to
develop cell culture processes more quickly and implement perfusion
more efficiently.”
Image Files for
Downloading:
Photo Link BIOSTAT STR bioreactorFor perfusion
cell culture application Repligen’s XCell™ ATF cell retention
control technology will be integrated into SSB’s BIOSTAT® STR
large-scale single-use bioreactors
Photo Link Repligen XCell™ ATFRepligen’s XCell™
ATF cell retention device is shown to significantly increase
bioreactor productivity; shown is the single-use XCell™ ATF 10
Photo Link ambr 250ht perfusion bioreactorSSB’s recently
launched ambr® 250ht perfusion bioreactor system is equipped with
Repligen’s KrosFlo® hollow fiber filter technology
About Sartorius Stedim
BiotechSartorius Stedim Biotech is a leading international
supplier of products and services that enable the biopharmaceutical
industry to develop and manufacture drugs safely and efficiently.
As a total solutions provider, Sartorius Stedim Biotech offers a
portfolio covering nearly all steps of biopharmaceutical
manufacture. The company focuses on single-use technologies and
value-added services to meet the rapidly changing technology
requirements of the industry it serves. Headquartered in Aubagne,
France, Sartorius Stedim Biotech is quoted on the Eurolist of
Euronext Paris. With its own manufacturing and R&D sites in
Europe, North America and Asia and an international network of
sales companies, Sartorius Stedim Biotech has a global reach. In
2017, the company employed approx. 5,100 people, and earned sales
revenue of €1,081.0 million.
For further information, visit
www.sartorius.com.
This press release contains statements about the
future development of the Sartorius Stedim Biotech Group. We cannot
guarantee that the content of these statements will actually apply
because these statements are based upon assumptions and estimates
that harbor certain risks and uncertainties.
About Repligen
CorporationRepligen Corporation (NASDAQ:RGEN) is a global
bioprocessing company that develops and commercializes highly
innovative products that deliver cost and process efficiencies to
biological drug manufacturers worldwide. The Company’s portfolio
includes protein products (Protein A affinity ligands, cell culture
growth factors), chromatography products (OPUS® pre-packed columns,
chromatography resins, ELISA kits) and filtration products
(including XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF
cassettes, and Spectrum KrosFlo™ hollow fiber TFF cartridges and
systems). The XCell™ ATF Systems, available in stainless steel and
single-use configurations, are used upstream to continuously
eliminate waste from a bioreactor, to concentrate cells and
increase product yield. Repligen’s corporate headquarters are in
Waltham, MA (USA), with additional administrative and manufacturing
operations in Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden
and Ravensburg, Germany.
For further information, visit
www.repligen.com.
The following constitutes a “Safe Harbor”
statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking statements, which
are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Investors are
cautioned that statements in this press release which are not
strictly historical statements, including, without limitation,
express or implied statements regarding Repligen’s partnership with
Sartorius Stedim Biotech, the impact of a single control system on
Repligen’s end users, and the future financial performance of
Repligen constitute forward-looking statements identified by words
like “believe,” “expect,” “may,” “will,” “should,” “seek,”
“anticipate,” or “could” and similar expressions. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including, without limitation, risks
associated with: our ability to successfully grow our bioprocessing
business, including as a result of acquisition, commercialization
or partnership opportunities; our ability to successfully integrate
any acquisitions, our ability to develop and commercialize products
and the market acceptance of our products; reduced demand for our
products that adversely impacts our future revenues, cash flows,
results of operations and financial condition; our ability to
compete with larger, better financed bioprocessing, pharmaceutical
and biotechnology companies; our compliance with all Food and Drug
Administration and EMEA regulations; our volatile stock price; and
other risks detailed in Repligen’s most recent Annual Report on
Form 10-K on file with the Securities and Exchange Commission and
the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those Repligen contemplated by these
forward-looking statements. These forward looking statements
reflect management’s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date hereof except as required by law.
Contacts:
For Sartorius Stedim
Biotech:
Dominic
Grone
Corporate
Communications
Sartorius Corporate Administration GmbH Phone: +49
(0)551.308.3324
Email: dominic.grone@sartorius.com
For Repligen:
Sondra NewmanSenior Director Investor
RelationsPhone: 781-419-1881Email: snewman@repligen.com
Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/d7943d34-ce7e-4c7d-8369-502ef1a62e66
http://www.globenewswire.com/NewsRoom/AttachmentNg/3c4625e0-3a0b-42b4-81d4-4554de5f393d
http://www.globenewswire.com/NewsRoom/AttachmentNg/ceeecd36-a6fd-44b3-ba8d-969ae51ee32c
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024